Moderna (MRNA) Expected to Announce Earnings on Thursday

Moderna (NASDAQ:MRNA) is expected to be posting its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Moderna to post earnings of ($2.93) per share and revenue of $977.11 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Moderna Stock Up 0.4 %

Shares of Moderna stock opened at $35.90 on Thursday. The firm has a market cap of $13.82 billion, a P/E ratio of -3.87 and a beta of 1.59. Moderna has a fifty-two week low of $29.25 and a fifty-two week high of $170.47. The business has a 50-day moving average price of $38.35 and a 200 day moving average price of $53.34.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 2,664 shares of company stock worth $115,210 over the last ninety days. Company insiders own 15.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Wolfe Research began coverage on Moderna in a report on Friday, November 15th. They issued an “underperform” rating and a $40.00 price objective for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Friday, November 8th. Hsbc Global Res raised Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Evercore ISI lowered their target price on Moderna from $60.00 to $50.00 and set an “in-line” rating for the company in a report on Monday, January 27th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $40.00 target price on shares of Moderna in a report on Tuesday. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $60.63.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.